Clinical Trial Update: A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MK-0893's effect on glucagon-induced glycemic excursions in healthy male participants following intravenous administration of glucagon,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GLUCAGON (GLUCAGON)
• Insulin (insulin)
• MK-0893
• Sandostatine (octreotide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED